Blue Trust Inc. Raises Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

Blue Trust Inc. grew its position in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 73.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 3,075 shares of the company’s stock after acquiring an additional 1,299 shares during the quarter. Blue Trust Inc.’s holdings in 10x Genomics were worth $44,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of TXG. GAMMA Investing LLC boosted its holdings in shares of 10x Genomics by 451.8% in the third quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock valued at $35,000 after purchasing an additional 1,265 shares during the period. Capital Performance Advisors LLP bought a new stake in 10x Genomics during the 3rd quarter valued at $35,000. Sound Income Strategies LLC purchased a new stake in shares of 10x Genomics in the 3rd quarter worth $46,000. Venturi Wealth Management LLC grew its position in shares of 10x Genomics by 1,108.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock worth $55,000 after buying an additional 2,240 shares in the last quarter. Finally, First Horizon Advisors Inc. increased its stake in shares of 10x Genomics by 53.3% during the third quarter. First Horizon Advisors Inc. now owns 2,910 shares of the company’s stock valued at $66,000 after buying an additional 1,012 shares during the period. 84.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 10x Genomics in a research note on Saturday, February 1st. UBS Group lowered their price target on shares of 10x Genomics from $25.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, October 30th. The Goldman Sachs Group cut their price objective on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating on the stock in a report on Wednesday, October 30th. JPMorgan Chase & Co. lowered their target price on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, October 30th. Finally, Morgan Stanley dropped their target price on 10x Genomics from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $23.86.

10x Genomics Stock Down 2.7 %

10x Genomics stock opened at $14.25 on Monday. The stock has a 50-day moving average price of $15.06 and a 200 day moving average price of $17.62. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of -9.31 and a beta of 1.85. 10x Genomics, Inc. has a 52 week low of $12.95 and a 52 week high of $51.22.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.